Abstract
Introduction: An algorithmic approach, termed the prolonged clot time profile (PROCT), consisting of initial screening with prothrombin time (PT) and activated partial thromboplastin time (aPTT), reflexive mixing studies if indicated, and follow-up assays depending on initial testing results, offers an efficient approach to delineate the etiology of a prolonged PT/aPTT. Herein, we present the outcomes of the PROCT in the outpatient setting. Methods: In this retrospective study, we reviewed medical records of consecutive outpatients who had prolonged PT and/or aPTT noted in the routine coagulation laboratory and who had PROCT ordered in our institutional Special Coagulation Laboratory between 2010 and 2017. Results: One hundred and six patients, median age 55 years (IQR 30-67), met our study criteria. Twenty-nine patients had normal PT/aPTT, while 77 had persistent abnormalities and underwent reflexive testing. A prolonged PT, aPTT, or PT and aPTT was noted in 27 (35%), 27 (35%), and 23 (30%) respectively. Forty-nine (64%) had an acquired condition, 17 (22%) had a congenital condition, 7 (9%) had unclear etiology, and 4 (5%) were the result of laboratory artifact. The most common known cause of an isolated prolonged PT in our study was vitamin K deficiency in 8 (10%), the most common cause of an isolated prolonged aPTT was lupus anticoagulant in 4 (5%), and the most common cause of prolonged PT and aPTT was liver disease in 11 (14%). Conclusion: Prolonged PT/aPTT have a wide range of causes, including artifactual prolongation or abnormalities in secondary hemostasis due to both inherited and acquired conditions.
Original language | English (US) |
---|---|
Pages (from-to) | 209-215 |
Number of pages | 7 |
Journal | International Journal of Laboratory Hematology |
Volume | 44 |
Issue number | 1 |
DOIs | |
State | Published - Feb 2022 |
Externally published | Yes |
Bibliographical note
Funding Information:Rajiv K Pruthi has received honoraria for attending advisory boards from CSL Behring, Genentech Inc., Bayer Healthcare AG, HEMA Biologics, Instrumentation Laboratory, and Merck. The rest of the authors have no financial disclosures or conflicts of interest Dr Hazim and Dr Ruan performed analysis and interpretation of data, drafting of manuscript, and edits to revised drafts. Dr Khodadadi performed analysis and interpretation of data, acquisition of data, and drafting of manuscript. Joshua P. Slusser BS assisted in data analysis. Dr Marshall and Dr Pruthi performed conception and design, drafting of manuscript, and edits to revised drafts.
Publisher Copyright:
© 2021 John Wiley & Sons Ltd
PubMed: MeSH publication types
- Journal Article